Rich Kruzynski RPh
Mr. Kruzynski has over 30 years of experience in the healthcare industry. He was part of the founding management team of PharMEDium Services, LLC in Lake Forest, IL in 2003, and served as its President until its 2015 acquisition by Amerisource Bergen Corporation for over $2.5 billion. Under his leadership, PharMEDium developed a broad range of sterile intravenous and epidural compounding admixture services that have become critical in the industry serving hospital pharmacies, with their need for anticipatory compounded sterile products.
Mr. Kruzynski’s knowledge of the sterile compounding industry’s quality and regulatory requirements has made him a key thought leader in the field. A licensed pharmacist, his participation as an expert panelist on several American Society of Health-System Pharmacists work groups, including the AHSP Guidelines on Outsourcing Sterile Compounding Services and the ASHP Foundation Outsourcing Sterile Products Preparation Contractor Assessment Tool, helped enable the establishment of standards for IV preparation and quality score-carding of outsourcing operations. In 2013, he participated in many meetings on Capitol Hill, assisting with education and discussions with various committees (e.g. Senate –HELP, and House – Energy and Commerce) and congressional offices about the services of the outsourced sterile compounding industry, as the Washington legislators worked toward passage of the federal Drug Quality and Security Act (DQSA). This law created a new section of the Food, Drug, and Cosmetic Act (“503B”) in which the category “outsourcing facility” now requires registration with the FDA at the federal level.
Before joining PharMEDium in 2003, Mr. Kruzynski founded the COMPASS compounding program and led business development for Baxter Healthcare Corporation’s premixed drug program. He holds U.S. patents for unique label designs for IV compounded preparations. He serves on the Board of Directors for etectRx, a technology company in the digital market for medication adherence technologies.
Mr. Kruzynski is a graduate of the University of Pittsburgh, School of Pharmacy. He earned his MBA from the University of Chicago.